Longhand
Category: AI in Healthcare
AI-powered platform for early detection and monitoring of Parkinson’s disease using digital handwriting analysis. Longhand was founded in 2023. The company is led by Akhil Chaturvedi. Based in Palo Alto, California, USA. Team size: 10-50. Total funding raised: $2.6 million. Latest round: Seed. Key investors include General Catalyst, Y Combinator, Rebel Fund, Afore Capital.
- Founded
- 2023
- Headquarters
- Palo Alto, California, USA
- Team size
- 10-50
- Total funding
- $2.6 million
Value proposition
Enables fast, non-invasive, and early screening for Parkinson’s by analyzing subtle changes in digital handwriting, potentially years before traditional diagnosis.
Products and solutions
Digital handwriting assessment tool (web/mobile), Clinician dashboard with risk scoring, API integrations for EHRs, Research analytics suite for pharmaceutical partners
Unique value
Leverages machine learning on digital handwriting and drawing tasks to detect micro-motor impairments indicative of early-stage Parkinson's, often before traditional clinical symptoms appear.
Target customer
Neurologists, movement disorder specialists, hospitals, clinics, and pharmaceutical companies conducting clinical trials.
Industries served
Healthcare, Pharmaceuticals, Medical Research
Technology advantage
Proprietary algorithms that analyze hundreds of features from digital writing tasks, offering higher sensitivity than conventional methods without requiring new hardware beyond a tablet and stylus.
How they differentiate
Focuses on digital handwriting analysis, a clinically validated method capturing fine motor control and cognitive-motor integration, rather than relying solely on wearable sensors or typing patterns.
Main competitors
Rune Labs, NeuraMetrix, Kinetikos Medical Technologies
Key partnerships
Stanford Medicine, UCSF Memory & Aging Center
Notable customers
Stanford Medicine Neurology Department (Pilot)
Major milestones
Closed $2.6M seed round in June 2024, Featured in Forbes 30 Under 30 for Healthcare (2024), Completed multi-site IRB-approved study validating algorithm accuracy against gold-standard clinical assessments
Growth metrics
Data collected from over 500 patients during initial pilot studies across three major US neurology centers.
Market positioning
Positioned as an easy-to-deploy adjunct diagnostic tool that integrates into existing clinical workflows using standard tablets.
Geographic focus
United States
Patents and IP
N/A
About Akhil Chaturvedi
Akhil Chaturvedi is a data science and machine learning professional with experience at Headspace, focusing on human-centric solutions. His role as CEO of Longhand could not be publicly verified.
Official website: https://www.longhand.ai